Subscriber Authentication Point
lvrea
Home All issues Volume 25 / No 3 (Mai 2016) Réanimation, 25 3 (2016) 287-295 References
Free Access
Issue
Réanimation
Volume 25, Number 3, Mai 2016
Infectieux
Page(s) 287 - 295
Section Mise Au Point / Update
DOI https://doi.org/10.1007/s13546-016-1180-9
Published online 18 February 2016
  • Dellinger RP, Levy MM, Rhodes A, et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228 [CrossRef] [PubMed] [Google Scholar]
  • Kumar A, Ellis P, Arabi Y, et al (2009) Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 136:1237–48 [CrossRef] [PubMed] [Google Scholar]
  • Meehan TP, Fine MJ, Krumholz HM, et al (1997) Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 278:2080–4 [CrossRef] [PubMed] [Google Scholar]
  • Dennesen PJ, van der Ven AJ, Kessels AG, et al (2001) Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 163:1371–5 [CrossRef] [PubMed] [Google Scholar]
  • Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363:600–7 [CrossRef] [PubMed] [Google Scholar]
  • Mandell LA, Bartlett JG, Dowell SF, et al (2003) Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37:1405–33 [CrossRef] [PubMed] [Google Scholar]
  • File TM Jr (2004) Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 39:S159–S64 [CrossRef] [PubMed] [Google Scholar]
  • Niederman MS, Mandell LA, Anzueto A, et al (2001) Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730–54 [CrossRef] [PubMed] [Google Scholar]
  • Corona A, Wilson AP, Grassi M, et al (2004) Prospective audit of bacteraemia management in a university hospital ICU using a general strategy of short-course monotherapy. J Antimicrob Chemother 54:809–17 [CrossRef] [PubMed] [Google Scholar]
  • Sawyer RG, Claridge JA, Nathens AB, et al (2015) Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med 372:1996–2005 [CrossRef] [PubMed] [Google Scholar]
  • Bassetti M, De Waele JJ, Eggimann P, et al (2015) Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 41:776–95 [CrossRef] [PubMed] [Google Scholar]
  • Paterson DL, Rice LB (2003) Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis 36:1006–12 [CrossRef] [PubMed] [Google Scholar]
  • 2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95 [CrossRef] [PubMed] [Google Scholar]
  • Christ-Crain M, Opal SM (2010) Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 14:203 [CrossRef] [PubMed] [Google Scholar]
  • Shehabi Y, Seppelt I (2008) Pro/Con debate: is procalcitonin useful for guiding antibiotic decision making in critically ill patients? Crit Care 12:211 [CrossRef] [PubMed] [Google Scholar]
  • Barraud D, Gibot S (2009) Apport des marqueurs biologiques de l’infection aux urgences et en réanimation. In: Boles JM, Bollaert PE, Jaeger A, et al (eds) Réanimation Médicale. Masson, Paris, pp 988–92 [Google Scholar]
  • Kaplan JM, Wong HR (2011) Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med 12:165–173 [CrossRef] [PubMed] [Google Scholar]
  • Schuetz P, Christ-Crain M, Muller B (2009) Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype? Swiss Med Wkly 139:318–26 [PubMed] [Google Scholar]
  • Gibot S, Bene MC, Noel R, et al (2012) Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 186:65–71 [CrossRef] [PubMed] [Google Scholar]
  • Dupuy AM, Kuster N, Lizard G, et al (2013) Performance evaluation of human cytokines profiles obtained by various multiplexed-based technologies underlines a need for standardization. Clin Chem Lab Med 51:1385–93 [CrossRef] [PubMed] [Google Scholar]
  • Pierrakos C, Vincent JL (2010) Sepsis biomarkers: a review. Crit Care 14:R15 [CrossRef] [PubMed] [Google Scholar]
  • Ehl S, Gering B, Bartmann P, et al (1997) C reactive protein is a useful marker for guiding duration of antibiotic therapy in suspected neonatal bacterial infection. Pediatrics 99:216–21 [CrossRef] [PubMed] [Google Scholar]
  • Bomela HN, Ballot DE, Cory BJ, et al (2000) Use of C reactive protein to guide duration of empiric antibiotic therapy in suspected early neonatal sepsis. Pediatr Infect Dis J 19:531–5 [CrossRef] [PubMed] [Google Scholar]
  • Jaswal RS, Kaushal RK, Goel A, et al (2003) Role of C reactive protein in deciding duration of antibiotic therapy in neonatal septicemia. Indian Pediatr 40:880–3 [PubMed] [Google Scholar]
  • Quenot JP, Luyt CE, Roche N, et al (2013) Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy. Ann Intensive Care 3:21 [CrossRef] [PubMed] [Google Scholar]
  • Oliveira CF, Botoni FA, Oliveira CR, et al (2013) Procalcitonin versus C reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit Care Med 41:2336–43 [CrossRef] [PubMed] [Google Scholar]
  • Simon L, Gauvin F, Amre DK, et al (2004) Serum procalcitonin and C reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–17 [CrossRef] [PubMed] [Google Scholar]
  • Tang BM, Eslick GD, Craig JC, et al (2007) Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 7:210–7 [CrossRef] [PubMed] [Google Scholar]
  • Uzzan B, Cohen R, Nicolas P, et al (2006) Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 34:1996–2003 [CrossRef] [PubMed] [Google Scholar]
  • Reinhart K, Karzai W, Meisner M (2000) Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med 26:1193–200 [CrossRef] [PubMed] [Google Scholar]
  • Bouadma L, Luyt CE, Tubach F, et al (2010) Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375:463–74 [Google Scholar]
  • Layios N, Lambermont B, Canivet JL, et al (2012) Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med 40:2304–9 [CrossRef] [PubMed] [Google Scholar]
  • Annane D, Maxime V, Faller JP, et al (2013) Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open pii: e002186 [Google Scholar]
  • Verduri A, Luppi F, D'Amico R, et al (2015) Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS One 10:e0118241 [CrossRef] [PubMed] [Google Scholar]
  • Schuetz P, Briel M, Mueller B (2013) Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections. JAMA 309:717–8 [CrossRef] [PubMed] [Google Scholar]
  • Jensen JU, Hein L, Lundgren B, et al (2011) Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 39:2048–58 [CrossRef] [PubMed] [Google Scholar]
  • Shehabi Y, Sterba M, Garrett PM, et al (2014) Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med 190:1102–10 [CrossRef] [PubMed] [Google Scholar]
  • Harbarth S, Holeckova K, Froidevaux C, et al (2001) Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 164:396–402 [CrossRef] [PubMed] [Google Scholar]
  • Luyt CE, Combes A, Reynaud C, et al (2008) Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med 34:1434–40 [CrossRef] [PubMed] [Google Scholar]
  • Stolz D, Smyrnios N, Eggimann P, et al (2009) Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 34:1364–75 [CrossRef] [PubMed] [Google Scholar]
  • Christ-Crain M, Stolz D, Bingisser R, et al (2006) Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174:84–93 [CrossRef] [PubMed] [Google Scholar]
  • Li H, Luo YF, Blackwell TS, et al (2011) Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections. Antimicrob Agents Chemother 55:5900–6 [CrossRef] [PubMed] [Google Scholar]
  • Schuetz P, Briel M, Christ-Crain M, et al (2012) Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 55:651–62 [CrossRef] [PubMed] [Google Scholar]
  • Prkno A, Wacker C, Brunkhorst FM, et al (2013) Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock — a systematic review and meta-analysis. Crit Care 17:R291 [CrossRef] [PubMed] [Google Scholar]
  • Schuetz P, Christ-Crain M, Thomann R, et al (2009) Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302:1059–66 [CrossRef] [PubMed] [Google Scholar]
  • Briel M, Schuetz P, Mueller B, et al (2008) Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 168:2000–2007; discussion 2007–2008 [CrossRef] [PubMed] [Google Scholar]
  • Albrich WC, Dusemund F, Bucher B, et al (2012) Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”: an international, multicenter poststudy survey (ProREAL). Arch Intern Med 172:715–22 [CrossRef] [PubMed] [Google Scholar]
  • Heyland DK, Johnson AP, Reynolds SC, et al (2011) Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 39:1792–9 [CrossRef] [PubMed] [Google Scholar]
  • Hochreiter M, Kohler T, Schweiger AM, et al (2009) Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 13:R83 [CrossRef] [PubMed] [Google Scholar]
  • Nobre V, Harbarth S, Graf JD, et al (2008) Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 177:498–505 [CrossRef] [PubMed] [Google Scholar]
  • Schroeder S, Hochreiter M, Koehler T, et al (2009) Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 394:221–6 [CrossRef] [PubMed] [Google Scholar]
  • Kip MM, Kusters R, IJzerman MJ, et al (2015) A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis. J Med Econ 18:944–53 [CrossRef] [PubMed] [Google Scholar]
  • Dupuy AM, Philippart F, Pean Y, et al (2013) Role of biomarkers in the management of antibiotic therapy: an expert panel review I: currently available biomarkers for clinical use in acute infections. Ann Intensive Care 3:22 [CrossRef] [PubMed] [Google Scholar]
  • Long W, Deng X, Zhang Y, et al (2011) Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 16:819–24 [CrossRef] [PubMed] [Google Scholar]
  • Drozdov D, Schwarz S, Kutz A, et al (2015) Procalcitonin and pyuria-based algorithm reduces antibiotic use in urinary tract infections: a randomized controlled trial. BMC Med 13:104 [CrossRef] [PubMed] [Google Scholar]
  • Huang TS, Huang SS, Shyu YC, et al (2014) A procalcitonin-based algorithm to guide antibiotic therapy in secondary peritonitis following emergency surgery: a prospective study with propensity score matching analysis. PLoS One 9:e90539 [CrossRef] [PubMed] [Google Scholar]
  • Hohn A, Schroeder S, Gehrt A, et al (2013) Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock. BMC Infect Dis 13:158 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.